Building giants or selling science? The Nordic capital agenda

The Nordics are undisputedly a global powerhouse for innovation and early-stage science. Yet, the region often struggles to scale these innovations into independent, global industrial players. Too often, our most promising assets are acquired by international pharma giants before they reach their full commercial potential.

In this high-level panel, we bring together the region’s heavyweight investors, managing the largest pools of capital, to discuss the strategic roadmap for 2026 and beyond. Do we have the financial depth and risk appetite to back companies ”all the way,” or is the early-exit model a necessity? We debate the power of syndication, the need for larger ticket sizes, and what it will actually take for Nordic Venture Capital to build the next Novo Nordisk.

Panelists includes:

Andreas Lindblom, Managing Partner, Sciety
Ulrica Slåne Bjerne, CIO, Arctic Aurora LifeScience
Max Odlander, Partner, HealthCap
Everett Kamin, CIO, Gemini Capital Partners & CIO, Silverstein Dream Foundation

All moderated by: Nina Rawal, Investment Committee Member, We Venture Capital

 

Funding the Future of Health: A Nordic Investor Perspective

What does the future of healthcare look like through the lens of those who fund it? Join a panel of premier Nordic investors as they explore the next wave of MedTech breakthroughs. The discussion will delve into where the region’s biggest investment opportunities lie, how geopolitical shifts impact funding timelines, and how we turn brilliant Scandinavian science into sustainable, global businesses.

Panelists includes:

Svana Gunnarsdóttir, Co-founder & Managing Partner, Frumtak Ventures
Karin Leire, Investment Manager, Segula Medical Acceleration
Kristofer Klerfalk, Managing Partner, Life Science Invest
Fredrik Andersson, CEO, Bonnier Healthcare

All moderated by: Stina Wallmark, Investment Director, VOIMA Ventures

The Grand Tour: Continental European Life Science Family Offices share perspectives and insights

Follow us on a great journey through Europe on where continental European Life Science Family Offices share perspectives and insights. We’ll talk Europe but also zoom in on specific markets – how does it work in the Nordics, Belgium, London, Spain, Germany, Austria, Switzerland, and so on? This is a journey where we will venture through both time and space with Europe and with Family Offices as the guiding light.

Panelists includes:
Melissa Simon, Partner, Wieland Capital
Laurens De Vries, Investor, Opdorp Finance: Vereeckens Family Office
Maria Nyåkern, Founder & Investor, Nyakern Nexus Investments 
All moderated by: Felix Borrebaeck, Business Developer andVenture Writer, BioStock

All or Nothing: How Family Offices Play Life Science

Family offices answer to no one – no LPs, no exit deadline. They play their own money, on their own timeline. In life science, where a drug can take 15 years to reach approval and one failed trial can wipe out everything overnight, that patience is an advantage few others can afford. No fund to raise, no clock to beat – do FO:s even need a strategy? Join us to find out.

Panelists include:

Laurent Pacheco, Managing Partner, IFOAH & Partner, Solas BioVentures
Hugo Mörse, Partner, Bonit Capital & Managing Director, Leksell Social Ventures
Jan Erik Smith, Partner, GOBIA Enterprises
Moderated by: Everett Kamin, CIO at Gemini Capital Partners & CIO at Silverstein Dream Foundation

Agenda - Investing in Life science 2026

08:00 Registration & Coffee

08:45  Welcoming remarks, BioStock

08:50  Building giants or selling science? The Nordic capital agenda

Andreas Lindblom, Managing Partner, Sciety
Ulrica Slåne Bjerne, CIO, Arctic Aurora LifeScience
Max Odlander, Partner, HealthCap
Everett Kamin, CIO at Gemini Capital Partners & CIO at Silverstein Dream Foundation
Moderated by: Nina Rawal, Investment Committee Member, We Venture Capital

Company presentations

09:30 Annexin Pharmaceuticals, Anders Haegerstrand, CEO
09:45 Neola Medical, Hanna Sjöström, CEO
09:55 RedHot Diagnostics, Henrik Rundgren, Board Member
10:05 Endoriz Pharma, Hanne Evenbratt, CEO
10:15 Biomedical Bonding, Michael Malkoch, CEO

10:25 Coffee & Networking

Company presentations

10:55 Cantargia, Hilde Steineger, CEO
11:10 Fluoguide, Morten Albrechtsen, CEO
11:25 Cinclus Pharma, Christer Ahlberg, CEO
11:40 Ambusol, Frederic Telander, Chair
11:55 SynAct Pharma, Jeppe Øvlesen, CEO

12:10 Lunch & Networking

13:10 All or Nothing: How Family Offices Play Life Science

Laurent Pacheco, Managing Partner, IFOAH & Partner, Solas BioVentures
Hugo Mörse, Partner, Bonit Capital & Managing Director, Leksell Social Ventures

Jan Erik Smith, Partner, GOBIA Enterprises
Moderated by: Everett Kamin, CIO at Gemini Capital Partners & CIO at Silverstein Dream Foundation

Company presentations

13:45 Abarceo Pharma, Adam Bruce, CEO
14:00 Amplio Pharma, Marguerite Mensonides, CEO
14:15 Isofol Medical, Petter S Lindqvist, CEO
14:30 Initiator Pharma, Annette Säfholm, COO

14:45 Coffee & networking

Company presentations

15:15 Oxcia, Ulrika Warpman Berglund, CEO
15:30 OncoZenge, Stian Kildal, CEO
15:45 Gasporox, Märta Lewander Xu, CEO
16:00 MedVasc, Cathrin Johansson, CEO

16:15 Funding the Future of Health: A Nordic Investor Perspective

Svana Gunnarsdóttir, Co-founder & Managing Partner, Frumtak Ventures
Karin Leire, Investment Manager, Segula Medical Acceleration
Kristofer Klerfalk, Managing Partner, Life Science Invest
Fredrik Andersson, CEO, Bonnier Healthcare
Moderated by: Stina Wallmark, Investment Director, VOIMA Ventures

Company presentations

16:50 BioInvent International, Björn Frendéus, CSO
17:05 Resother Pharma, Anders Kronborg, CEO
17:20 Sorbus Biomedical, Roger Rönn, Founder & CSO

17:35 The Grand Tour: Continental European Life Science Family Offices share perspectives and insights

Melissa Simon, Partner, Wieland Capital
Laurens de Vries, Life science investments, Opdorp Finance: Vereecken’s Family Office
Maria Nyåkern, Founder & Investor, Nyakern Nexus Investments 

Moderated by: Felix Borrebaeck, Venture Writer & Business Developer, BioStock

18:10-18:55 After work

Learn more about the innovators at Investing in Life Science 2026